Europe Has Missed Antimicrobial Resistance Targets
The region is falling short of goals to curb antibiotic use and save lives from resistant infections.
Updated on Sept. 30, 2026 in COVID-19
Live Poll
Should national governments implement stricter regulations to curb the overuse of antibiotics?
Europe is on track to miss four out of five of its 2030 targets for curbing antimicrobial resistance. These goals were established to combat a crisis where antibiotic-resistant infections cause more than 35,000 deaths annually across the continent.
Why it matters
The failure to meet these reduction targets poses a growing threat to public health as the misuse and overuse of antibiotics accelerate the emergence of resistant bacteria. Addressing these consumption patterns is critical to preserving the efficacy of existing medical treatments.
Official monitoring indicates that antibiotic consumption in 2024 is 2% higher than the 2019 baseline, directly contradicting the goal of a 20% reduction. It remains unknown whether policy adjustments can course-correct before the 2030 deadline.
The players
European Partnership on One Health AMR
A collaborative coalition of over 50 organizations working to manage antimicrobial resistance across the region.
The details
Antimicrobial resistance occurs when germs develop the ability to defeat the drugs designed to kill them, often driven by the unnecessary use of antibiotics. To address this, the European Partnership on One Health AMR is utilizing surveillance systems to monitor drug usage patterns. Additionally, new pharmaceutical regulations now offer transferable data exclusivity vouchers to incentivize companies to prioritize the development of new, effective antimicrobial therapies.
Timeline
2019 served as the baseline year for establishing regional antibiotic consumption reduction targets.
EU governments formally set the 20% consumption reduction targets in 2023.
Antibiotic consumption levels for 2024 showed a 2% increase over the 2019 baseline.
The deadline for achieving the five European antimicrobial resistance targets is 2030.
Health Landscape
These trends sit against the backdrop of the EU pharmaceutical package, which includes incentives like transferable data exclusivity vouchers to bolster antibiotic innovation. While development is supported, the regional struggle to curb consumption levels suggests that treatment innovation alone may not solve the resistance crisis.
Understanding the risks of antibiotic resistance is essential for every patient, particularly regarding the need to use these medications only when prescribed for bacterial infections. If you have concerns about the necessity of an antibiotic for an illness, it is worth discussing with your doctor.
The takeaway
The persistent rise in antibiotic use despite regional targets signals a need for greater vigilance in how these drugs are utilized. Tracking the emergence of resistant strains and engaging in clear communication with your physician about infection treatment remains the best practice for individual health.
Further reading
For broader context on how health systems manage infectious threats, visit COVID-19.
Source note: This article includes information reported by Euractiv DE.
Live Poll
Should national governments implement stricter regulations to curb the overuse of antibiotics?
